LEADTEK BIOMED INC., established in 2000, began investing in Vigin Gene Technology to enter the smart healthcare and health management industries. Vigin focuses on the development of heart rate variability (HRV) analysis, electrocardiogram (ECG), and wireless applications, holding the largest market share in Taiwan. The company’s medical equipment is widely used in major hospitals across Taiwan and China. In 2010, LEADTEK launched the amor health brand, which aims to provide high-quality health products and services. Amor's flagship products include the H1 heart rate fitness tracker (2014), the H2 health wristband (2018), and the H2 Plus wearable ECG recorder (2020). The H2 Plus integrates AI-based health management and continuous monitoring, helping reduce hospital readmission rates by 75% when used by discharged patients. In 2021, the amor HRV Guard was introduced as a next-generation autonomic nervous system testing device that provides quick and accurate health data. LEADTEK BIOMED INC. also acquired the Alvital brand in 2019, known for its advanced blood oxygen monitors, which gained recognition during the COVID-19 pandemic and received international certifications, including U.S. FDA and Japan PMDA. In 2023, LEADTEK BIOMED INC. launched a home sleep testing service and continues to expand its offerings in the smart healthcare ecosystem. The company integrates AIoT technologies for personalized health management, offering wearable devices and data analytics platforms to monitor heart health, blood pressure, blood sugar, and more. LEADTEK BIOMED INC. is present in over 2,000 retail outlets across Taiwan and collaborates with more than 200 medical institutions.

AMOR